Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

Sep 8, 2026 · Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Convening the 2026 Semi-annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 31
"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Conditional Approval for Marketing of Velinotamig InjectionAug 28
"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 Injection for the Indication of Chronic Hepatitis BAug 19
"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 InjectionAug 18

All Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases